Trial Profile
A three-part phase 1b multicenter, open-label study to determine the safety and efficacy of [fam-] trastuzumab deruxtecan in combination with avelumab and/or a DDR inhibitor
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 01 Nov 2018
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Trastuzumab-deruxtecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 01 Nov 2018 New trial record